Overview

Perifosine and Docetaxel in Patients With Relapsed Epithelial Ovarian Cancer

Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find out if a combination treatment of perifosine and docetaxel will help shrink or slow the growth of cancer cells in recurrent ovarian cancer. The safety of this combination treatment will also be studied.
Phase:
Phase 1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Keryx Biopharmaceuticals
Treatments:
Docetaxel